Reklāma

IFRX Forex ziņas

InflaRx Reports Positive Topline Results From SAD Phase I Study With C5aR Inhibitor INF904

Biotechnology company InflaRx N.V. (IFRX) announced Monday topline results from the single ascending dose (SAD) part of its randomized, double-blind, placebo-controlled Phase I trial of the orally administered, low molecular weight C5aR inhibitor INF904.

RTTNews | 642 days ago

Noteikumi | Privātums | Lapas karte | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.15403	GBPUSD	1.35613	AUDUSD	0.649
USDJPY	143.972	USDCAD	1.35934	USDCHF	0.81158